

For Immediate Release:

Burtonsville, Maryland: October 26, 2005

The FDA announces ChiRhoStim™ (*Human Secretin for injection*) as the new name for Human Secretin

(Burtonsville, MD) ChiRhoClin Inc. has just received approval from the Food and Drug Administration (FDA) to name human secretin, ChiRhoStim™ (*Human Secretin for injection*). Dr. Edward Purich (C.E.O. of ChiRhoClin) stated “I am please to have the proprietary name ChiRhoStim™ associated with Human Secretin. ChiRhoStim™ is a pioneering secretin product and will facilitate the diagnosis of patients with pancreas disease.”

ChiRhoClin, Inc. a pharmaceutical manufacturer was marketing ChiRhoStim™ under its generic name Human Secretin®. With this announcement CRC, will now begin using the proprietary name ChiRhoStim™ for the product. ChiRhoStim™ is a diagnostic for pancreatic function testing and Zollinger-Ellison Syndrome (gastrinomas testing), and facilitates cannulation of the pancreatic ducts during ERCP. In 2004, ChiRhoStim™ was approved by the FDA and has a shelf life of two years in the freezer and storage up to six months at room temperature.

We are notifying the medical community that Human Secretin has changed its name to ChiRhoStim™ and is commercially available. If you would like more information, please visit our web site at www.ChiRhoStim.com or call 1-877-272-4888. ChiRhoClin, Inc. is the leader in secretin based drug products and is striving toward developing new indications and methodologies for ChiRhoStim™ to aid the GI community in diagnosing pancreatic diseases.